Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital.
Eur J Dermatol
; 33(3): 265-269, 2023 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-37594334
ABSTRACT
BACKGROUND:
Propranolol is currently considered the first-line therapy for problematic infantile hemangiomas (IH), the most common benign vascular neoplasm of infancy.OBJECTIVES:
We present a retrospective observational study aimed at assessing the efficacy of propranolol in 44 IH patients. MATERIALS &METHODS:
A nine-year retrospective review considering clinicodemographical and therapy-related variables was performed on medical records of infants treated for IH with oral propranolol. Each lesion was assessed through a numeric severity score based on size and colour both at baseline and after treatment conclusion (p <0.05 was considered statistically significant).RESULTS:
Complete remission was achieved in 90.7% cases of IH with a general mean improvement in severity of 94.94%. No severe adverse effects were reported. Preterm patients showed a superior response compared to term infants, even though the difference was not significant (p=0.185).CONCLUSION:
Propranolol showed high efficacy in terms of safety profile and cosmetic results. Prematurity and precocious therapy could be linked to a superior response.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemangioma Capilar
/
Neoplasias Vasculares
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article